- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Institutional Culture and Sensitive Investigations
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Lisa M. Dwyer
Events 18 results
Webinar
January 29, 2025
Summary of FDA’s New Final Guidance: Scientific Information on Unapproved Uses
Conference
September 5, 2024
17th Annual King & Spalding Medical Device Summit
Speaking Engagement
January 10, 2024
Lisa Dwyer to Interview Dr. Califf at CES Conference
Webinar
November 30, 2023
FDA’s Latest Salvo in the LDT (Laboratory Developed Tests) Wars
Conference
November 7, 2023
Pharmaceutical University 2023
Webinar
October 31, 2023
How to Launch a Telehealth Clinic: Legal Considerations
Conference
September 7, 2023
16th Annual King & Spalding Medical Device Summit
Conference
March 8, 2023
California Life Sciences Summit
Speaking Engagement
November 30, 2022
Lisa Dwyer to Speak on Food and Drug Law Institutes Virtual Event
Conference
November 1, 2022
Pharmaceutical University 2022
Webinar
October 25, 2022
FDA’s Changing Approach to Regulating Clinical Decision Support Software
Conference
January 12, 2017
An Introduction to the 21st Century Cures Act